RightFit
RecruitingPhase 4

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis.

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Time periods mentioned: 4 weeks

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "At week 16, patients with remaining BSA ˃3% will be given HALOG ointment 0.1% to apply BID for 4 weeks."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Official eligibility criteria

Inclusion Criteria: 1. Male or female adult ≥ 18 years of age; 2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis as defined by * BSA 10% * PGA ≥3 * PASI ≥12 3. Must be a candidate for phototherapy and/or systemic therapy 4. Females of childbearing potential (FCBP) must have a negative serum pregnancy test at Screening and negative urine pregnancy test at Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide. Exclusion Criteria: 1. Non-plaque forms of psoriasis 2. Women of childbearing potential who are pregnant, intend to become pregnant, or are lactating 3. Presence of significant uncontrolled medical condition that in the opinion of the investigator would affect patient safety during the trial. 4. Active or untreated latent tuberculosis (TB)

Study sites (1)

NJ